A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual cycle in female patients ...

The mass layoffs of federal workers under Health Secretary Robert F. Kennedy Jr. have impaired data-gathering on critical ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy ... according to the health technology assessment (HTA) agency. It is estimated that ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta ... crises and fatal events which require further assessment," and the company has pulled the drug from the market ...

ShareHealthcare is more than just treating diseases; it is the heartbeat of a thriving society, the foundation upon which progress is built. A state’s strength is measured not just by its economic ...

In a new study, researchers found that the inflammation behind painful episodes in sickle cell disease are correlated with ...

Period-driven inflammation could influence the risk of pain events among women with sickle cell disease. Levels of C-reactive ...

Sickle cell conditions are genetic blood disorders that affect haemoglobin, the molecule in red blood cells responsible for carrying oxygen throughout the body. While both sickle cell trait and sickle ...

wiping out teams working on research about adults with cognitive disabilities and sickle cell disease. Work likely to be halted by the cuts includes the collection of data for studying Americans ...